evolocumab
amgen
['evolocumab', 'fourier']
fourier-ole median fu &gt;7y .
events during open label treatment with evolocumab, patients treated initially 23% reduction in cv death 15% in primary endpoint a clear legacy effect!! #esccongress 
Interventional cardiologist. Cardiology, Hospital Universitario de San Juan Alicante. Spain